NCT06928090Enrolling by invitation
Efficacy and Safety of DTG/3TC in Treatment-naïve HIV-1 Infected Patients
A Retrospective Observational Study of Efficacy and Safety of DTG/3TC(Dolutegravir/Lamivudine) in Treatment-naïve HIV-1 Infected Patients From at Real-life Cohort in Korea
Source: ClinicalTrials.gov · Last updated 15 Apr 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Non-interventional, retrospective, single arm study of individuals who have initiated a DTG/3TC regimen. Medical chart will be reviewed by the investigators. Naive subjects will be identified by the clinic database as having initiated DTG/3TC.
- Status (registry)
- Enrolling by invitation
- Study type
- Observational
- Enrollment
- 200 (estimated)
- First submitted
- 27 Mar 2025
- Start date
- Jan 2025
- Primary completion date
- Dec 2025
- Lead sponsor
- Chungnam National University Hospital
- Diseases
- HIV
- NCT number
- NCT06928090
What you commit to
- Study type: Observational
- Planned participants: 200
- From Jan 2025 to the primary completion date, Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous antiretroviral treatment
Other illness
- HIV-2 diagnosis
Who the study is looking for
- HIV-1 diagnosis
- Prescribed DTG/3TC alone to manage HIV-1 infection as initial antiretroviral treatment at the study centers
Age in the registry: 19 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Chungnam National University Hospital, 282 Munwha-ro Coordinator of this site? Confirm its status | Daejeon | South Korea | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.